Abstract
Acute myeloid leukemia (AML) patients with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) often have a poor prognosis, even after hematopoietic stem cell transplantation (HSCT). We report a case of AML with FLT3-ITD identified upon initial diagnosis, who received HSCT at complete remission after 3 consecutive chemotherapies. However, the patient relapsed when the same FLT3-ITD clone emerged, and finally died. Retrospective analysis revealed an allelic ratio of FLT3-ITD/wild type of 1.1 and 0.0096 upon initial diagnosis and before HSCT, respectively. The detection of any minimal residual FLT3-ITD clone before HSCT is useful in the treatment of AML with FLT3-ITD.
| Original language | English |
|---|---|
| Pages (from-to) | 79-83 |
| Number of pages | 5 |
| Journal | Acta Medica Okayama |
| Volume | 71 |
| Issue number | 1 |
| Publication status | Published - 2017 |
Fingerprint
Keywords
- Acute myeloid leukemia
- FLT3-ITD
- HSCT
- Minimal residual disease
- Relapse
ASJC Scopus subject areas
- Medicine(all)
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Iwasaki, Y., Nishiuchi, R., Aoe, M., Takahashi, T., Watanabe, H., Tokorotani, C., Kikkawa, K., & Shimada, A. (2017). Positive minimal residual disease of FLT3-ITD before hematopoietic stem cell transplantation resulted in a poor prognosis of an acute myeloid leukemia. Acta Medica Okayama, 71(1), 79-83.